Get the Stockscreener App
30.14
3.57%
1.04
After Hours:
30.05
-0.09
-0.30%
Rapt Therapeutics Inc stock is traded at $30.14, with a volume of 532.57K.
It is up +3.57% in the last 24 hours and up +166.73% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$29.10
Open:
$29.26
24h Volume:
532.57K
Relative Volume:
3.41
Market Cap:
$498.45M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-9.882
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+14.25%
1M Performance:
+166.73%
6M Performance:
+239.41%
1Y Performance:
+89.32%
1-Day Range:
$28.07
$31.76
1-Week Range:
$24.34
$31.76
52-Week Range:
$5.6652
$31.76
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
30.14 | 481.25M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Why RAPT Therapeutics Inc. stock is seen as undervaluedQuarterly Investment Review & Free Reliable Trade Execution Plans - newser.com
How analysts rate RAPT Therapeutics Inc. stock today2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com
Why RAPT Therapeutics Inc. (0RA0) stock stays on top picksWeekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Is RAPT Therapeutics Inc. (0RA) stock bottoming after sell offQuarterly Profit Summary & High Conviction Buy Zone Picks - newser.com
How RAPT Therapeutics Inc. (0RA) stock performs in volatility spikesJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Will RAPT Therapeutics Inc. stock maintain growth story2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
Can swing trading help recover from RAPT Therapeutics Inc. lossesJuly 2025 Fed Impact & Community Consensus Picks - newser.com
How to use a screener to detect RAPT Therapeutics Inc. breakoutsFed Meeting & Comprehensive Market Scan Reports - newser.com
Published on: 2025-10-02 21:38:33 - newser.com
Will RAPT Therapeutics Inc. (0RA) stock draw ESG focused fundsRisk Management & Daily Profit Focused Screening - newser.com
Clear Street Maintains RAPT Therapeutics (RAPT) Buy Recommendation - Nasdaq
Published on: 2025-09-30 02:47:57 - newser.com
Rapt Therapeutics stock price target raised to $41 from $24 at Clear Street - Investing.com Canada
What hedge fund moves indicate for RAPT Therapeutics Inc. (0RA) stockJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - newser.com
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial - Investing.com Nigeria
RAPT Therapeutics Announces FDA Clearance of IND - GlobeNewswire
Rapt Therapeutics announces FDA clearance to proceed to phase 2b trial of RPT904 in food allergy - MarketScreener
RAPT Therapeutics' Food Allergy Drug Gets FDA Clearance for Phase 2b Trial - MarketScreener
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy - The Manila Times
RAPT Therapeutics Announces FDA Clearance for IND Application to Initiate Phase 2b Trial of RPT904 in Food Allergy Treatment - Quiver Quantitative
How to build a dashboard for RAPT Therapeutics Inc. stockJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
FDA Green Light: RAPT Therapeutics' Novel Food Allergy Treatment Heads to Critical Phase 2b Trial - Stock Titan
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.68%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):